Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Hammond

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Open Forum Infectious Diseases|June 10, 2024
Viral SARS-CoV-2 Rebound Rates in Linked Commercial Pharmacy-Based Testing and Health Care ClaimsScott P Kelly, Lisa M McEwen, Magnus Isaksson, et al.
Clinical Genetics|June 22, 2021
How to deal with uncertainty in prenatal genomics: A systematic review of guidelines and policiesJasmijn E Klapwijk, Malgorzata I Srebniak, Attie T J I Go, et al.
Prenatal Diagnosis|April 27, 2022
Factors that impact on women's decision-making around prenatal genomic tests: An international discrete choice surveyJames Buchanan, Melissa Hill, Caroline M Vass, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2002
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variantsRaymond F Schinazi, John Mellors, Holly Bazmi, et al.
The Lancet. Infectious Diseases|July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trialEdward Weinstein, Roger Paredes, Annie Gardner, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2020
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Nature Communications|October 19, 2021
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Open Forum Infectious Diseases|June 10, 2024
Viral SARS-CoV-2 Rebound Rates in Linked Commercial Pharmacy-Based Testing and Health Care ClaimsScott P Kelly, Lisa M McEwen, Magnus Isaksson, et al.
Clinical Genetics|June 22, 2021
How to deal with uncertainty in prenatal genomics: A systematic review of guidelines and policiesJasmijn E Klapwijk, Malgorzata I Srebniak, Attie T J I Go, et al.
Prenatal Diagnosis|April 27, 2022
Factors that impact on women's decision-making around prenatal genomic tests: An international discrete choice surveyJames Buchanan, Melissa Hill, Caroline M Vass, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2002
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variantsRaymond F Schinazi, John Mellors, Holly Bazmi, et al.
The Lancet. Infectious Diseases|July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trialEdward Weinstein, Roger Paredes, Annie Gardner, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2020
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Nature Communications|October 19, 2021
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Pageof 7